Zarnestra News and Research

RSS

Zarnestra is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. Also called R115777 and tipifarnib.

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

$Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma$

Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

13 Dec 2021

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

7 Dec 2004